Using CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Considering 3-Year Follow-Up Data of Cilta-Cel in Multiple Myeloma

Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.

Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.

Efficacy of Cilta-Cel Is Maintained in Early Relapsed Multiple Myeloma

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Earlier CAR T-Cell Therapy Benefits Functional High-Risk Group in RRMM

Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Patient Selection Factors for Earlier Use of CAR T-Cell Therapy

Binod Dhakal, MD, MS, discusses selecting patients for chimeric antigen receptor T-cell therapy by considering each patient’s condition and logistics.